Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
215
-
Total 13F shares, excl. options
-
82.1M
-
Shares change
-
+8.9M
-
Total reported value, excl. options
-
$1.05B
-
Value change
-
+$185M
-
Put/Call ratio
-
0.86
-
Number of buys
-
124
-
Number of sells
-
-88
-
Price
-
$12.83
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q3 2022
245 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2022.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 215 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.1M shares
of 123M outstanding shares and own 66.62% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15.3M shares), STATE STREET CORP (7.56M shares), VANGUARD GROUP INC (6.14M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (4.9M shares), LSV ASSET MANAGEMENT (3.39M shares), RENAISSANCE TECHNOLOGIES LLC (2.23M shares), DIMENSIONAL FUND ADVISORS LP (2.14M shares), D. E. Shaw & Co., Inc. (1.87M shares), TWO SIGMA INVESTMENTS, LP (1.73M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.69M shares).
This table shows the top 215 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.